{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:17:06Z","timestamp":1787008626217,"version":"build-2736575974"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"Supplement_5","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), particularly cases caused by multidrug-resistant organisms, often require newer antibiotic treatment. The efficacy and safety of newer antibiotics compared with generic antibiotics in randomized controlled trials (RCTs) have not been evaluated before.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this systematic review, we searched RCTs in the United States National Library of Medicine (PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), Scopus, Ovid MEDLINE, ClinicalTrials.gov, and Google Scholar databases published between 2013 and 2025 (registration no. CRD42023476481). The primary efficacy end point was the 28-day all-cause mortality rate, and the secondary efficacy end points were clinical and microbiological response. The safety end point was nephrotoxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 8 eligible RCTs involving 2881 patients with HABP\/VABP (1450 treated with newer antibiotics and 1431 treated with generic antibiotics). The meta-analysis did not reveal any significant differences between newer and generic antibiotics in the 28-day all-cause mortality rate (risk ratio [RR], 0.97; 95% confidence interval [CI], .72\u20131.30; I2 = 30%), the clinical response (1.04 [.93\u20131.17]; I2 = 35%), or the microbiological response (1.05 [.89\u20131.24]; I2 = 52%). However, newer antibiotics showed significant lower occurrences of nephrotoxicity than regimens with a colistin component (RR, 0.30 [95% CI, .11\u2013.79]; I2 = 0%). In the subgroup analysis, newer antibiotic regimens demonstrated significant improvement in microbiological eradication of carbapenem-resistant gram-negative bacilli (RR, 1.50 [95% CI, 1.18\u20131.90]; I2 = 0%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Newer antibiotics and generic drugs showed similar efficacy and safety in treating HABP\/VABP. The superiority of newer antibiotics in the microbiological eradication of carbapenem-resistant gram-negative bacilli could suggest that future trials should be targeted to those patients to improve understanding of the therapeutic use of these antibiotics and the pathophysiology of these conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciag045","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T12:41:42Z","timestamp":1771072902000},"page":"S116-S125","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Newer Antibiotics Versus Generic Antibiotics for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia: A Systematic Review and Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1093","volume":"82","author":[{"given":"Anh T K","family":"Nguyen","sequence":"first","affiliation":[{"name":"Oxford University Clinical Research Unit , Ho Chi Minh City ,","place":["Vietnam"]},{"name":"ADVANCE-ID Network, Saw Swee Hock School of Public Health, National University of Singapore ,","place":["Singapore"]},{"name":"Hospital for Tropical Diseases , Ho Chi Minh City ,","place":["Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Paterson","sequence":"additional","affiliation":[{"name":"ADVANCE-ID Network, Saw Swee Hock School of Public Health, National University of Singapore ,","place":["Singapore"]},{"name":"Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore ,","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0216-9550","authenticated-orcid":false,"given":"Yin","family":"Mo","sequence":"additional","affiliation":[{"name":"ADVANCE-ID Network, Saw Swee Hock School of Public Health, National University of Singapore ,","place":["Singapore"]},{"name":"Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore ,","place":["Singapore"]},{"name":"Division of Infectious Diseases, University Medicine Cluster, National University Hospital ,","place":["Singapore"]},{"name":"Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford , Oxford ,","place":["United Kingdom"]},{"name":"Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Ezure","sequence":"additional","affiliation":[{"name":"The University of Queensland, UQ Centre for Clinical Research , Brisbane, Queensland ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pham Thanh","family":"Duy","sequence":"additional","affiliation":[{"name":"Oxford University Clinical Research Unit , Ho Chi Minh City ,","place":["Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4666-9813","authenticated-orcid":false,"given":"C Louise","family":"Thwaites","sequence":"additional","affiliation":[{"name":"Oxford University Clinical Research Unit , Ho Chi Minh City ,","place":["Vietnam"]},{"name":"Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford , Oxford ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"2026060203212660100_ciag045-B1","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care\u2013associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"2026060203212660100_ciag045-B2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.ajic.2021.04.077","article-title":"International Nosocomial Infection Control Consortium (INICC) report, data summary of 45 countries for 2013\u20132018, adult and pediatric units, device-associated module","volume":"49","author":"Rosenthal","year":"2021","journal-title":"Am J Infect Control"},{"key":"2026060203212660100_ciag045-B3","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1378\/chest.122.6.2115","article-title":"Epidemiology and outcomes of ventilator-associated pneumonia in a large US database","volume":"122","author":"Rello","year":"2002","journal-title":"Chest"},{"key":"2026060203212660100_ciag045-B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/ice.2019.296","article-title":"Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015\u20132017","volume":"41","author":"Weiner-Lastinger","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026060203212660100_ciag045-B5","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1086\/653053","article-title":"Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia","volume":"51","author":"Jones","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2026060203212660100_ciag045-B6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jinf.2014.10.004","article-title":"Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia: validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms","volume":"70","author":"Martin-Loeches","year":"2015","journal-title":"J Infect"},{"key":"2026060203212660100_ciag045-B7","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s00134-012-2808-5","article-title":"Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors","volume":"39","author":"Martin-Loeches","year":"2013","journal-title":"Intensive Care Med"},{"key":"2026060203212660100_ciag045-B8","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijantimicag.2014.01.007","article-title":"Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009\u20132012","volume":"43","author":"Sader","year":"2014","journal-title":"Int J Antimicrobial Agents"},{"key":"2026060203212660100_ciag045-B9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","author":"American Thoracic Society, Infectious Diseases Society of America","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2026060203212660100_ciag045-B10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1183\/09031936.06.00049105","article-title":"Appropriateness and delay to initiate therapy in ventilator-associated pneumonia","volume":"27","author":"Luna","year":"2006","journal-title":"Eur Respir J"},{"key":"2026060203212660100_ciag045-B11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12879-017-2383-z","article-title":"Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis","volume":"17","author":"Zilberberg","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2026060203212660100_ciag045-B12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"2026060203212660100_ciag045-B13","volume-title":"WHO Bacterial priority pathogens list 2024 bacterial pathogens of public health importance, to guide research, development, and strategies to prevent and control antimicrobial resistance","year":"2024"},{"key":"2026060203212660100_ciag045-B14","doi-asserted-by":"crossref","DOI":"10.15620\/cdc:82532","volume-title":"Antibiotic resistance threats in the United States, 2019","author":"US Centers for Disease Control and Prevention","year":"2019"},{"key":"2026060203212660100_ciag045-B15","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026060203212660100_ciag045-B16","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"2026060203212660100_ciag045-B17","doi-asserted-by":"crossref","first-page":"c1432","DOI":"10.1136\/bmj.c1432","article-title":"The new CONSORT statement","volume":"340","author":"Antes","year":"2010","journal-title":"BMJ"},{"key":"2026060203212660100_ciag045-B18","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026060203212660100_ciag045-B19","volume-title":"Cochrane handbook for systematic reviews of interventions. Version 6.4 (updated August 2023)","author":"Higgins","year":"2023"},{"key":"2026060203212660100_ciag045-B20","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane (Oxford, UK), 2023","author":"Deeks"},{"key":"2026060203212660100_ciag045-B21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines. 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2026060203212660100_ciag045-B22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Mental Health"},{"key":"2026060203212660100_ciag045-B23","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026060203212660100_ciag045-B24","doi-asserted-by":"crossref","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study)","volume":"73","author":"Titov","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026060203212660100_ciag045-B25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026060203212660100_ciag045-B26","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane\u2013tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2026060203212660100_ciag045-B27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026060203212660100_ciag045-B28","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026060203212660100_ciag045-B29","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam\u2013durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii\u2013calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026060203212660100_ciag045-B30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.11613\/BM.2021.010502","article-title":"Sample size, power and effect size revisited: simplified and practical approaches in pre-clinical, clinical and laboratory studies","volume":"31","author":"Serdar","year":"2021","journal-title":"Biochem Med (Online)"},{"key":"2026060203212660100_ciag045-B31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-021-01061-7","article-title":"Penetration of antibacterial agents into pulmonary epithelial lining fluid: an update","volume":"61","author":"Drwiega","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"2026060203212660100_ciag045-B32","first-page":"746","article-title":"An introduction to multiplicity issues in clinical trials: the what, why, when and how","volume":"46","author":"Li","year":"2016","journal-title":"Int J Epidemiol"},{"key":"2026060203212660100_ciag045-B33","doi-asserted-by":"crossref","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","volume":"79","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/Supplement_5\/S116\/68447058\/ciag045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/Supplement_5\/S116\/68447058\/ciag045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T07:21:42Z","timestamp":1780384902000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/Supplement_5\/S116\/8699689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":33,"journal-issue":{"issue":"Supplement_5","published-online":{"date-parts":[[2026,6,2]]},"published-print":{"date-parts":[[2026,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag045","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,15]]},"published":{"date-parts":[[2026,6,2]]}}}